Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

NCT06705478

Status	RECRUITING
Phase	Phase 2
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment	186 participants

Key Eligibility Criteria

Inclusion (12)

- Documented HIV-1 infection.
- Diagnosis of MDD.
- On current ART regimen for at least 90 days prior to study entry with no interruption in treatment greater than 7 consecutive days.
- No plans to change ART while on study.
- Plasma HIV-1 RNA levels of less than 200 copies/mL obtained within 90 days prior to enrollment.

... and 7 more (see full listing online)

Exclusion (36)

- Active suicidality, and/or severe MDD, psychotic disorders, manic or hypomanic symptoms occurring in the context of bipolar disorder type I or II, or cyclothymic disorder, or another current Axis I diagnosis judged by the investigator to interfere with the trial.
- Study candidate self-report of depressive symptoms that have persisted for over 50 percent of waking hours and for over 50 percent of days over the 24 months prior to study entry.
- Severe, active alcohol or substance use disorder by DSM-5-TR criteria in the 6 months prior to study entry.
- Active alcohol or substance use judged by the investigator to interfere with the trial.
- Any acute infection within 14 days prior to study entry.

... and 31 more (see full listing online)

Locations (40 total)

Alabama CRS, Birmingham, Alabama, United States
University of California, Los Angeles CARE Center CRS, Los Angeles, California, United States
UCSD Antiviral Research Center CRS, San Diego, California, United States
... and 37 more locations